JP2013545730A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545730A5
JP2013545730A5 JP2013535311A JP2013535311A JP2013545730A5 JP 2013545730 A5 JP2013545730 A5 JP 2013545730A5 JP 2013535311 A JP2013535311 A JP 2013535311A JP 2013535311 A JP2013535311 A JP 2013535311A JP 2013545730 A5 JP2013545730 A5 JP 2013545730A5
Authority
JP
Japan
Prior art keywords
compound
neuropathic pain
pain
syndrome
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013535311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545730A (ja
JP6257326B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/005452 external-priority patent/WO2012055567A2/en
Publication of JP2013545730A publication Critical patent/JP2013545730A/ja
Publication of JP2013545730A5 publication Critical patent/JP2013545730A5/ja
Application granted granted Critical
Publication of JP6257326B2 publication Critical patent/JP6257326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013535311A 2010-10-29 2011-10-28 神経因性疼痛におけるマロノニトリルアミドの使用 Active JP6257326B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40819510P 2010-10-29 2010-10-29
EP10014122 2010-10-29
US61/408,195 2010-10-29
EP10014122.5 2010-10-29
PCT/EP2011/005452 WO2012055567A2 (en) 2010-10-29 2011-10-28 Use of malononitrilamides in neuropathic pain

Publications (3)

Publication Number Publication Date
JP2013545730A JP2013545730A (ja) 2013-12-26
JP2013545730A5 true JP2013545730A5 (US20070167479A1-20070719-C00034.png) 2014-10-16
JP6257326B2 JP6257326B2 (ja) 2018-01-10

Family

ID=44992853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535311A Active JP6257326B2 (ja) 2010-10-29 2011-10-28 神経因性疼痛におけるマロノニトリルアミドの使用

Country Status (16)

Country Link
US (2) US20130217737A1 (US20070167479A1-20070719-C00034.png)
EP (1) EP2632451B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP6257326B2 (US20070167479A1-20070719-C00034.png)
CN (1) CN103179962B (US20070167479A1-20070719-C00034.png)
CA (1) CA2814371C (US20070167479A1-20070719-C00034.png)
DK (1) DK2632451T3 (US20070167479A1-20070719-C00034.png)
ES (1) ES2655084T3 (US20070167479A1-20070719-C00034.png)
HR (1) HRP20171848T1 (US20070167479A1-20070719-C00034.png)
HU (1) HUE034890T2 (US20070167479A1-20070719-C00034.png)
LT (1) LT2632451T (US20070167479A1-20070719-C00034.png)
NO (1) NO2632451T3 (US20070167479A1-20070719-C00034.png)
PL (1) PL2632451T3 (US20070167479A1-20070719-C00034.png)
PT (1) PT2632451T (US20070167479A1-20070719-C00034.png)
RS (1) RS56713B1 (US20070167479A1-20070719-C00034.png)
SI (1) SI2632451T1 (US20070167479A1-20070719-C00034.png)
WO (1) WO2012055567A2 (US20070167479A1-20070719-C00034.png)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
CN109069502B (zh) * 2016-09-24 2021-08-06 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
EP3928772B1 (en) * 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
HU222234B1 (hu) 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2727628B1 (fr) * 1994-12-02 1997-01-10 Roussel Uclaf Application des derives de 3-cycloalkyl-propanamide a titre de medicaments analgesiques
US6566395B1 (en) * 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US8957098B2 (en) * 2010-08-24 2015-02-17 Algiax Pharmaceuticals Gmbh Use of leflunomide and malononitrilamides

Similar Documents

Publication Publication Date Title
JP2013545730A5 (US20070167479A1-20070719-C00034.png)
HRP20171848T1 (hr) Upotreba malononitrilamida za neuropatsku bol
JP2012530779A5 (US20070167479A1-20070719-C00034.png)
RU2012101947A (ru) Способы лечения и профилактики усталости
JP2016534063A5 (US20070167479A1-20070719-C00034.png)
JP2013526544A5 (US20070167479A1-20070719-C00034.png)
JP2009504763A5 (US20070167479A1-20070719-C00034.png)
JP2019515908A5 (US20070167479A1-20070719-C00034.png)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2015524423A5 (US20070167479A1-20070719-C00034.png)
RU2013113634A (ru) Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств
JP2015522018A5 (US20070167479A1-20070719-C00034.png)
JP2013519653A5 (US20070167479A1-20070719-C00034.png)
WO2008124824A1 (en) Dosages and methods for the treatment of cancer
JP2013518036A5 (US20070167479A1-20070719-C00034.png)
FI3681857T3 (fi) Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa
RU2019111096A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP2011518168A5 (US20070167479A1-20070719-C00034.png)
WO2008124823A1 (en) Method of treating melanoma
JP2014530204A5 (US20070167479A1-20070719-C00034.png)
RU2019102757A (ru) Производные этинила
JP2016537432A5 (US20070167479A1-20070719-C00034.png)
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени